Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE versus X TROZINE L A.
Cetirizine vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective second-generation H1-receptor antagonist that inhibits histamine release from mast cells and basophils, thereby reducing allergic symptoms.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
10 mg orally once daily; 5 mg orally once daily for mild symptoms
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 8.3 hours in healthy adults; extended to 20 hours in elderly and patients with renal impairment
Clinical Note
moderateCetirizine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone propionate."
Clinical Note
moderateLevocetirizine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Cyclosporine
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Primarily renal (60% unchanged in urine); minor biliary/fecal (10%)
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category A/B
Category C
Antihistamine
Antihistamine
"The metabolism of Cyclosporine can be decreased when combined with Levocetirizine."